PHATHOM PHARMACEUTICALS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period
PHATHOM PHARMACEUTICALS, INC. (PHAT) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period of 257.19 thousand shares for the 9-month period ending 2022-09-30, per its 10-Q/A filed 2022-11-09.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod · last filed 2022-11-09
- PHATHOM PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2022-09-30 was 167.64K shares.
- PHATHOM PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2022-06-30 was 65.24K shares.
- PHATHOM PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2022-03-31 was 24.31K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 9 month |
|---|---|---|---|
| 2022-09-30 | 167.64K shares derived: 10-Q/A 9 month − 10-Q 6 month · filed 2022-11-09 | 232.88K shares derived: sum of 2 quarters · filed 2022-11-09 | 257.19K shares 10-Q/A · filed 2022-11-09 |
| 2022-06-30 | 65.24K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-02 | 89.55K shares 10-Q · filed 2022-08-02 | |
| 2022-03-31 | 24.31K shares 10-Q · filed 2022-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 |